STOCK TITAN
  1. Home
  2. Sec-filings
  3. INBX
  4. [8-K] Inhibrx Biosciences, Inc. Reports Material Event

Inhibrx Biosciences shareholders back board, auditor

Inhibrx Biosciences, Inc. reported results from its 2026 Annual Meeting of Stockholders held online on June 3, 2026.

Filing Impact
(Moderate)
Filing Sentiment
(Negative)
Form Type
8-K

Rhea-AI Filing Summary

Inhibrx Biosciences, Inc. reported results from its 2026 Annual Meeting of Stockholders held online on June 3, 2026. A quorum of 11,541,232 shares was present, representing about 79% of the 14,607,286 common shares entitled to vote as of April 7, 2026.

Stockholders elected Class II directors Douglas G. Forsyth and Kimberly Manhard to serve until the 2029 Annual Meeting and until their successors are duly elected and qualified, or earlier death, resignation, or removal. Forsyth received 7,608,469 votes for and 1,463,474 withheld, with 2,469,289 broker non-votes. Manhard received 9,035,097 votes for and 36,846 withheld, with 2,469,289 broker non-votes.

Stockholders also ratified the appointment of BDO USA, P.C. as independent registered public accounting firm for the fiscal year ending December 31, 2026, with 11,510,478 votes for, 30,347 against, and 407 abstentions.

Positive

  • None.

Negative

  • None.
Item 5.07 Submission of Matters to a Vote of Security Holders Governance
Results of a shareholder vote on proposals at an annual or special meeting.
Shares outstanding entitled to vote 14,607,286 shares Common stock as of record date April 7, 2026
Quorum shares present 11,541,232 shares Shares present or represented by proxy at 2026 Annual Meeting
Quorum percentage approximately 79% Portion of outstanding shares entitled to vote represented at meeting
Votes for Forsyth 7,608,469 votes Election of Class II director Douglas G. Forsyth
Votes for Manhard 9,035,097 votes Election of Class II director Kimberly Manhard
Votes for auditor ratification 11,510,478 votes Ratification of BDO USA, P.C. as auditor for fiscal 2026
quorum financial
"a quorum of 11,541,232 shares, or approximately 79% of the outstanding shares entitled to vote, was present"
A quorum is the minimum number of members needed to officially hold a meeting or make decisions. It ensures that decisions are made with enough participation to represent the group’s interests, much like a majority must be present for a vote to be valid. For investors, understanding quorum is important because it affects when and how important company or organization decisions can be legally made.
broker non-votes financial
"Douglas G. Forsyth | 7,608,469 | 1,463,474 | 2,469,289"
Broker non-votes occur when a brokerage firm is unable to vote on a shareholder’s behalf during a company election or decision because the shareholder has not given specific voting instructions, and the broker is not allowed or chooses not to vote on certain matters. They are important because they can affect the outcome of votes, especially when the results are close, by effectively reducing the total number of votes cast.
independent registered public accounting firm financial
"BDO USA, P.C. as the Company’s independent registered public accounting firm for the fiscal year ending December 31, 2026"
An independent registered public accounting firm is an outside accounting company officially registered with the government regulator to examine and report on a public company's financial records and controls. Investors treat its reports like an impartial inspector’s certificate — they add credibility to financial statements, help spot errors or misleading claims, and reduce the risk that shareholders are relying on unchecked or biased numbers.
Annual Meeting of Stockholders financial
"The 2026 Annual Meeting of Stockholders (the “Annual Meeting”) of Inhibrx Biosciences, Inc."

FAQ

AI-generated questions and answers. How Rhea-AI works. Not financial advice.

What did Inhibrx Biosciences (INBX) shareholders vote on at the 2026 Annual Meeting?
Shareholders voted on electing two Class II directors and ratifying BDO USA, P.C. as independent registered public accounting firm for 2026. Both director nominees and the auditor ratification proposal received sufficient support to be approved.

Were Inhibrx Biosciences (INBX) director nominees elected at the 2026 Annual Meeting?
Yes. Douglas G. Forsyth and Kimberly Manhard were elected as Class II directors to serve until the 2029 Annual Meeting. Both received strong support, with Forsyth and Manhard each obtaining millions of votes in favor and limited withhold votes.

How many Inhibrx Biosciences (INBX) shares were represented at the 2026 Annual Meeting?
A quorum of 11,541,232 shares was present or represented by proxy, out of 14,607,286 common shares entitled to vote. This represented approximately 79% of outstanding shares as of the April 7, 2026 record date.

What were the vote results for Inhibrx Biosciences (INBX) auditor ratification in 2026?
Stockholders ratified the appointment of BDO USA, P.C. as independent registered public accounting firm for 2026, with 11,510,478 votes for, 30,347 against, and 407 abstentions. This indicates broad shareholder support for the company’s chosen auditor.

Who signed the Inhibrx Biosciences (INBX) 2026 Annual Meeting report?
The report was signed on behalf of Inhibrx Biosciences, Inc. by Leah Pollema, who serves as Vice President, General Counsel and Corporate Secretary. The signature confirms the company’s authorization and submission of the meeting results.

How many votes did Inhibrx Biosciences (INBX) director Kimberly Manhard receive?
Kimberly Manhard received 9,035,097 votes for election as a Class II director, with 36,846 votes withheld and 2,469,289 broker non-votes. This result reflects strong shareholder support for her continued service on the board.

AI-generated analysis. How Rhea-AI works. Not financial advice.

Understanding 8-K Material Events →
See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google
Add on Google
FALSE000200791900020079192026-06-032026-06-03

UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549  
FORM 8-K
CURRENT REPORT
Pursuant to Section 13 or 15(d)
of the Securities Exchange Act of 1934
Date of Report (Date of earliest event reported): June 3, 2026
INHIBRX BIOSCIENCES, INC.
(Exact name of registrant as specified in its charter)  
Delaware001-4203199-0613523
(State or other jurisdiction
of incorporation)		(Commission
File Number)		(IRS Employer
Identification No.)
11025 N. Torrey Pines Road, Suite 140
La Jolla, CA 92037
(Address of Principal Executive Offices and Zip Code)
Registrant’s telephone number, including area code: (858) 795-4220
Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:
☐    Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)
☐    Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)
☐    Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))
☐    Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))
Securities registered pursuant to Section 12(b) of the Act:
Title of each classTrading Symbol(s)Name of each exchange on which registered
Common Stock, par value $0.0001 per shareINBXThe Nasdaq Global Market
Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§240.12b-2 of this chapter).
Emerging growth company  ☒
If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act.  ☒



Item 5.07    Submission of Matters to a Vote of Security Holders.
The 2026 Annual Meeting of Stockholders (the “Annual Meeting”) of Inhibrx Biosciences, Inc. (the “Company”) was held on June 3, 2026 at 10:00 a.m. Pacific Time online in a virtual format. Of the Company’s 14,607,286 shares of common stock issued and outstanding and entitled to vote as of the record date of April 7, 2026, a quorum of 11,541,232 shares, or approximately 79% of the outstanding shares entitled to vote, was present virtually or represented by proxy. Each of the matters set forth below is described in detail in the Company’s definitive proxy statement filed with the Securities and Exchange Commission on April 23, 2026. The following actions were taken at the Annual Meeting:
Proposal 1
Election of the following nominees as Class II directors of the Company, nominated by the Company’s Board of Directors (the “Board of Directors”), each to serve until the 2029 Annual Meeting of Stockholders and until their respective successor is duly elected and qualified, or until their respective earlier death, resignation, or removal.
Votes ForVotes WithheldBroker Non-Votes
Douglas G. Forsyth7,608,4691,463,4742,469,289
Kimberly Manhard9,035,09736,8462,469,289
Proposal 2
Ratification of the appointment by the Audit Committee of the Board of Directors of BDO USA, P.C. as the Company’s independent registered public accounting firm for the fiscal year ending December 31, 2026.
Votes ForVotes AgainstVotes Abstained
11,510,47830,347407

SIGNATURES
Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.
Date: June 3, 2026
INHIBRX BIOSCIENCES, INC.
By:/s/ Leah Pollema
Name:Leah Pollema
Title:VP, General Counsel and Corporate Secretary

Source: View Original Filing on SEC EDGAR

Filing Exhibits & Attachments

3 documents

Other Documents

Keep reading

More on INBX

Trending in the feed

Open the live feed